Data gathered: December 26
AI Stock Analysis - Glaukos (GKOS)
Analysis generated September 30, 2024. Powered by Chat GPT.
Glaukos Corporation is a medical technology company focused on developing and commercializing novel ophthalmic products. The company's mission is to transform the treatment of glaucoma, one of the world's leading causes of blindness. Glaukos pioneered Micro-Invasive Glaucoma Surgery (MIGS) to deliver transformational outcomes for mild-to-moderate glaucoma patients. The company continues to advance a robust pipeline, including the expansion into new treatment modalities and further geographic markets.
Stock Alerts - Glaukos (GKOS)
 |
Glaukos | December 24 Insider Alert: Gilliam Joseph E is selling shares |
|
Glaukos | December 14 Insider Alert: Kliman Gilbert H is selling shares |
|
Glaukos | December 11 Price is up by 5.7% in the last 24h. |
|
Glaukos | December 6 Price is up by 5.1% in the last 24h. |
Alternative Data for Glaukos
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 29 | Sign up | Sign up | Sign up |
| Sentiment | 74 | Sign up | Sign up | Sign up |
| Webpage traffic | 17,000 | Sign up | Sign up | Sign up |
| Employee Rating | 90 | Sign up | Sign up | Sign up |
| Google Trends | 24 | Sign up | Sign up | Sign up |
| Patents | 61 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 224 | Sign up | Sign up | Sign up |
| Facebook Followers | 6,726 | Sign up | Sign up | Sign up |
| Instagram Followers | 3,116 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 826 | Sign up | Sign up | Sign up |
| Twitter Followers | 1,638 | Sign up | Sign up | Sign up |
| Twitter Mentions | 11 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 88 | Sign up | Sign up | Sign up |
| Linkedin Employees | 877 | Sign up | Sign up | Sign up |
About Glaukos
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.
| Price | $152.82 |
| Target Price | Sign up |
| Volume | 31,700 |
| Market Cap | $8.34B |
| Year Range | $96 - $152.82 |
| Dividend Yield | 0% |
| Analyst Rating | 83% buy |
| Industry | Medical Devices |
In the news
 |
Glaukos Co. (NYSE:GKOS) Receives Average Rating of “Moderate Buy” from BrokeragesDecember 24 - ETF Daily News |
|
Glaukos Co. (NYSE:GKOS) Shares Sold by Principal Financial Group Inc.December 24 - ETF Daily News |
 |
Glaukos Stock Down Despite NDA Submission of Epioxa to the FDADecember 24 - Yahoo |
|
Glaukos Co. (NYSE:GKOS) Director Gilbert H. Kliman Sells 10,000 SharesDecember 24 - ETF Daily News |
|
Joseph E. Gilliam Sells 3,328 Shares of Glaukos Co. (NYSE:GKOS) StockDecember 24 - ETF Daily News |
 |
Glaukos president sells $498,715 in stockDecember 23 - Investing.com |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 97M | 87M | 74M | -21M | -18M | -0.280 |
| Q2 '24 | 96M | 89M | 73M | -51M | -24M | -0.520 |
| Q1 '24 | 81M | 88M | 65M | -41M | -31M | -0.700 |
| Q4 '23 | 81M | 91M | 63M | -37M | -25M | -0.630 |
| Q3 '23 | 75M | 73M | 60M | -30M | -21M | -0.500 |
Insider Transactions View All
| Gilliam Joseph E filed to sell 102,169 shares at $150.4. December 23 '24 |
| Gilliam Joseph E filed to sell 103,461 shares at $149.5. December 23 '24 |
| Kliman Gilbert H filed to sell 32,336 shares at $150.3. December 23 '24 |
| Kliman Gilbert H filed to sell 32,336 shares at $144. December 13 '24 |
| Kliman Gilbert H filed to sell 32,336 shares at $130. September 11 '24 |
Similar companies
Read more about Glaukos (GKOS) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Glaukos?
The Market Cap of Glaukos is $8.34B.
What is the current stock price of Glaukos?
Currently, the price of one share of Glaukos stock is $152.82.
How can I analyze the GKOS stock price chart for investment decisions?
The GKOS stock price chart above provides a comprehensive visual representation of Glaukos' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Glaukos shares. Our platform offers an up-to-date GKOS stock price chart, along with technical data analysis and alternative data insights.
Does GKOS offer dividends to its shareholders?
As of our latest update, Glaukos (GKOS) does not offer dividends to its shareholders. Investors interested in Glaukos should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Glaukos?
Some of the similar stocks of Glaukos are Boston Scientific, Edwards Lifesciences, Intuitive Surgical, Medtronic, and Stryker.
.